Omeros (OMER) Scheduled to Post Quarterly Earnings on Wednesday

Omeros (NASDAQ:OMER) is scheduled to release its earnings data after the market closes on Wednesday, August 7th.

Omeros (NASDAQ:OMER) last issued its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.13).

Omeros Price Performance

NASDAQ OMER traded up $0.08 during trading hours on Tuesday, hitting $4.43. The company had a trading volume of 244,914 shares, compared to its average volume of 457,369. The firm’s 50 day moving average is $4.27 and its 200 day moving average is $3.89. The company has a market capitalization of $256.69 million, a price-to-earnings ratio of -2.39 and a beta of 1.45. Omeros has a fifty-two week low of $0.92 and a fifty-two week high of $5.68.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on OMER. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Tuesday, June 4th. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research report on Tuesday, July 30th.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.